Evolution of the Average Target: Stem, Inc.

Evolution of the Target Price: Stem, Inc.

Changes in Analyst Recommendations: Stem, Inc.

d889a159b1cab527deeadfafa.GPwYsoxeYT_4RgBel7x9aDPDx1uuXc1LhVeZche5xcg.V7Rwhe0NVwqWHzEmw_A4OwuPsG__b5gixmXzFkTWi_ooz1H10xQzfrEKRQ~6e286661b32d91108e5679501d835242
08-14 UBS Adjusts Price Target on Stem to $7 From $10.50, Keeps Neutral Rating MT
05-11 UBS Cuts Price Target on Stem to $10.50 From $12, Maintains Neutral Rating MT
03-10 UBS Adjusts Price Target on Stem to $12 From $18, Maintains Neutral Rating MT
25-10-31 UBS Adjusts Price Target on Stem Inc to $18 From $16, Maintains Neutral Rating MT
25-08-22 UBS Adjusts Stem Price Target to $16 From $8.60, Maintains Neutral Rating MT
25-04-14 UBS Downgrades Stem to Neutral From Buy, Cuts Price Target to $0.40 From $0.65 MT
25-03-07 UBS Adjusts Stem Price Target to $0.65 From $0.60, Maintains Buy Rating MT
24-11-08 UBS Trims Price Target on Stem to $0.60 From $1, Maintains Buy Rating MT
24-08-09 Susquehanna Downgrades Stem to Neutral From Positive, Adjusts Price Target to $0.50 From $2 MT
24-08-08 UBS Adjusts Price Target on Stem to $1 From $2.50, Maintains Buy Rating MT
24-08-07 TD Cowen Downgrades Stem to Hold From Buy, Adjusts PT to $1 From $4 MT
24-07-15 Susquehanna Trims Price Target on Stem to $2 From $2.50, Maintains Positive Rating MT
24-05-08 UBS Adjusts Price Target on Stem to $2.50 From $5, Maintains Buy Rating MT
24-04-11 Piper Sandler Trims Price Target on Stem to $2 From $3, Maintains Neutral Rating MT
24-03-22 Stem Shares Decline Following Downgrade From Goldman Sachs MT
24-03-22 Goldman Sachs Downgrades Stem to Neutral From Buy, Cuts Price Target to $2.50 From $5.50 MT
24-02-29 Susquehanna Trims Price Target on Stem to $4 From $5.50, Maintains Positive Rating MT
23-12-08 Morgan Stanley Cuts Price Target on Stem to $4 From $7, Maintains Equal-Weight Rating MT
23-11-03 Guggenheim Downgrades Stem to Neutral From Buy MT
23-11-01 Roth MKM Adjusts Price Target on Stem to $3.70 From $6, Maintains Neutral Rating MT
23-10-24 Barclays Trims Stem's Price Target to $5 From $6, Maintains Equalweight Rating MT
23-10-20 BNP Paribas Exane Initiates Stem With Neutral Rating, Price Target is $5 MT
23-10-17 Morgan Stanley Trims Price Target on STEM to $7 From $8, Keeps Equalweight Rating MT
23-10-17 Goldman Sachs Adjusts Price Target on Stem to $7 From $9.50, Maintains Buy Rating MT
23-10-06 Piper Sandler Trims Stem Price Target to $4 From $5, Maintains Neutral Rating MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
- +33.75%
+32.22%
+65.07%
+90.5%
+80%
+86.98%
+70.03%
- +25.33%
+54.59%
+97.98%
Average +63.65%
Weighted average by Cap. +42.74%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
6
Last Close Price
5.570USD
Average target price
7.450USD
Spread / Average Target
+33.75%
High Price Target
8.000USD
Spread / Highest target
+43.63%
Low Price Target
6.750USD
Spread / Lowest Target
+21.18%

Analyst Consensus Detail

Consensus revision (last 18 months)

Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
  1. Stock Market
  2. Stocks
  3. STEM Stock
  4. Consensus Stem, Inc.
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!